56 completed, 1 recruiting, 1 terminated, 1 withdrawn. 23 Phase 2, 19 Phase 3, 8 Phase 4, 4 Not applicable, 3 Phase 1.
Follow fluarix: new trials by email Literature Review of fluarix trials Research Report on fluarix
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Characterizing the Human Airway Immune Response to FluMist Vaccination FluMist, inactivated influenza vaccine, bronchoscopy - Healthy Young Adults, Influenza Vaccines | Phase 4 | Recruiting | Washington University School of Medicine | 30 | 2025-09-09 | 2025-09-17 |
| A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age mRNA-1010, Fluarix®, Influsplit® Tetra - Seasonal Influenza | Phase 3 | Completed | ModernaTX, Inc. | 40805 | 2024-09-16 | 2026-09-16 |
| A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Adults mRNA-1010, Egg-based Quadrivalent Influenza Vaccine, Adjuvanted Quadrivalent Influenza Vaccine - Influenza | Phase 2 | Completed | ModernaTX, Inc. | 172 | 2022-11-02 | 2025-11-24 |
| Study Describing the Immunogenicity and Safety of Quadrivalent Recombinant Influenza Vaccine (RIV4) Versus a Licensed Quadrivalent-inactivated Influenza Vaccine (IIV4) (Fluarix® Quadrivalent) in Participants 18 Years of Age and Older in South Korea Quadrivalent Recombinant Influenza Vaccine (RIV4), Quadrivalent inactivated influenza vaccine (IIV4) - Influenza (Healthy Volunteers) | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 301 | 2021-12-07 | 2025-09-11 |
| Immunogenicity Trial of Egg- Versus Non-Egg-Based Influenza Vaccines Among HCP Flublok, Flucelvax, Fluarix - Influenza | Phase 4 | Completed | Centers for Disease Control and Prevention | 944 | 2018-09-12 | 2024-07-22 |
| A Study to Evaluate the Safety and Immunogenicity of Seasonal Influenza Vaccine and an Adenovirus Serotype 26- Based Vaccine Encoding for the Respiratory Syncytial Virus Pre-fusion F Protein (Ad26.RSV.preF), With and Without Co-administration, in Adults Aged 60 Years and Older in Stable Health Ad26.RSV.preF, Fluarix, Placebo - Healthy | Phase 2 | Completed | Janssen Vaccines & Prevention B.V. | 180 | 2017-12-07 | 2025-02-04 |
| Evaluation of Antibody Response to High-Dose Seasonal Influenza Vaccination in Patients With Myeloid Malignancy Receiving Chemotherapy and Healthy Volunteers Trivalent Influenza Vaccine - Acute Myeloid Leukemia, Myelodysplastic Syndrome | Early Phase 1 | Completed | Roswell Park Cancer Institute | 130 | 2017-10-17 | 2023-06-06 |
| Influenza Vaccine Feasibility Study in Children With Persistent Asthma ccIIV4, IIV4 - Asthmatic | Phase 4 | Completed | Vanderbilt University Medical Center | 40 | 2016-10-10 | 2018-04-23 |
| Perturbing of HIV Reservoir With Immune Stimulation Fluarix, Pneumovax, Placebo - AIDS, HIV | Not applicable | Completed | University of California, San Diego | 54 | 2016-08-01 | 2022-08-24 |
| Qualitative, Qualitative, and Functional Studies Over the First Year in Measuring Immune System Response During the First Year of Therapy in Patients With Brain Tumors Hepatitis A Vaccine, Laboratory Biomarker Analysis, Tetanus Toxoid Vaccine - Astrocytoma, Glioma | Completed | Wake Forest University Health Sciences | 55 | 2016-05-01 | 2021-10-29 | |
| Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed, Ibrutinib, Laboratory Biomarker Analysis - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Completed | Jennifer Woyach | 42 | 2016-01-12 | 2026-04-06 |
| Influenza Vaccine Responses as a Means of Assessing Immune Competence in Chimeric Kidney/Stem Cell Transplant Recipients Influenza vaccine - Influenza | Completed | Northwestern University | 19 | 2015-10-01 | 2025-05-16 | |
| Safety and Immunogenicity of Three Seasonal Trivalent Influenza Vaccines in China Military Seasonal trivalent influenza vaccine, Anflu®, Seasonal trivalent influenza vaccine, VAXIGRIP, Seasonal trivalent influenza vaccine, Fluarix - Influenza | Phase 4 | Completed | Center for Disease Prevention and Control of Beijing Military Region | 292 | 2014-10-01 | 2015-12-29 |
| Safety and Immunogenicity Study of Influenza Vaccines in HIV-infected and HIV-uninfected Pregnant Women in Western Kenya Quadrivalent Inactivated Influenza Vaccine (QIV), Inactivated Polio Vaccine, Double Dose QIV - Influenza, Human, HIV | Phase 2 / Phase 3 | Withdrawn | Centers for Disease Control and Prevention | 2014-04-01 | 2014-04-10 | |
| Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine, Fluarix/Influsplit Tetra® (2013/2014 Season), in Adults 18 Years of Age and Older Fluarix/Influsplit Tetra® (2013-2014 season) - Influenza | Phase 3 | Completed | GlaxoSmithKline | 117 | 2013-07-11 | 2018-09-07 |
| Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine, Fluarix®/Influsplit SSW® (2013/2014 Season), in Adults 18 Years of Age and Older Fluarix/Influsplit SSW® (2013-2014 season) - Influenza | Phase 3 | Completed | GlaxoSmithKline | 120 | 2013-07-01 | 2018-09-07 |
| Immunogenicity and Safety of PrepandrixTM in Korean Subjects Aged 18 to 60 Years Old Prepandrix™, Fluarix™ - Influenza | Phase 4 | Completed | GlaxoSmithKline | 131 | 2012-12-05 | 2018-09-07 |
| Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine GSK2282512A When Administered to Children 6 to 35 Months of Age Quadrivalent influenza GSK2282512A vaccine, Fluarix - Influenza | Phase 3 | Completed | GlaxoSmithKline | 606 | 2012-11-01 | 2021-11-01 |
| A Study for Evaluation of Immunogenicity and Reactogenicity of Fluarix/Influsplit SSW 2012/2013 in People Aged 18 Years and Above Fluarix/Influsplit SSW 2012-2013 - Influenza | Phase 3 | Completed | GlaxoSmithKline | 119 | 2012-07-10 | 2018-09-07 |
| Trial to Evaluate Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2584786A in Healthy Children GSK Bio's influenza vaccine GSK2584786A, different formulations, GSK Bio's influenza vaccine GSK2321138A, Fluarix™ - Influenza, Influenza Vaccines | Phase 2 | Terminated | GlaxoSmithKline | 4 | 2010-09-30 | 2020-10-30 |
Showing 20 of 59. Sign in to see all of them.
Influenza, Human (52) · Tetanus (2) · Acquired Immunodeficiency Syndrome (1) · Asthma (1) · Astrocytoma (1) · Diphtheria (1) · Egg Hypersensitivity (1) · Glioma (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Myeloid, Acute (1) · Malaria (1) · Meningococcal Infections (1) · Myelodysplastic Syndromes (1) · Oligodendroglioma (1) · Orthomyxoviridae Infections (1)
GlaxoSmithKline (38) · Centers for Disease Control and Prevention (2) · ModernaTX, Inc. (2) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · Center for Disease Prevention and Control of Beijing Military Region (1) · Hualan Biological Engineering, Inc. (1) · Janssen Vaccines & Prevention B.V. (1) · Jennifer Woyach (1) · NanoPass Technologies Ltd (1) · Northwestern University (1) · Public Health England (1) · Roswell Park Cancer Institute (1) · Sanofi Pasteur, a Sanofi Company (1) · University of California, San Diego (1) · University of Massachusetts, Worcester (1)
United States (23) · Germany (14) · Belgium (12) · Netherlands (5) · Spain (5) · Sweden (5) · Estonia (3) · Norway (3) · South Korea (3) · United Kingdom (3) · Canada (2) · China (2) · France (2) · Mexico (2) · Taiwan (2)
Brendan Flannery, PhD (1) · Dongqi Gao, PhD (1) · Elizabeth A Griffiths (1) · Elizabeth Miller, MBBS FRCPath (1) · Fatimah Dawood, MD (1) · Jennifer Woyach, MD (1) · Joseph Leventhal, MD, PhD (1) · Joshua A Mott, PhD (1) · Kathryn M Edwards, MD (1) · Marc-Alain Widdowson, VetMB, MSc (1) · Mary Dawn T Co, MD (1) · Meredith L McMorrow, MD, MPH (1) · Nancy Otieno, MS (1)
PMID 22885014, PMID 29465480, PMID 18407382, PMID 19954075, PMID 20375709, PMID 20431425, PMID 23782962, PMID 23890405, PMID 25386965, PMID 25652873, PMID 25910919, PMID 26069949, PMID 32851411, PMID 34245243, PMID 34608724, PMID 36031405, PMID 38177116, PMID 38526550, PMID 40752250, PMID 42090792
P30CA012197 (1), R01AI118422 (1)